Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Internal Medicine Alert

RSS  

Articles

  • Pramlintide Acetate Injection (Symlin)

    By William T. Elliott, MD, FACP, and James Chan, PharmD, PhD Dr. Elliott is Chair, Formulary Committee, Northern California Kaiser Permanente; Associate Clinical Professor of Medicine, University of California, San Francisco; Dr. Chan is Pharmacy Quality and Outcomes Manager, Kaiser Permanente, Oakland, CA. Drs. Chan and Elliott report no financial relationships to this field of study. A synthetic analog of human amylin has been approved for the treatment of type 1 and type 2 diabetics. Pramlintide is a 37-amino acid peptide which differs from human amylin with substitution of three amino acids at positions 25, 28, and 29. It represents the first of a new class of amylinomimetic antidiabetic compounds. It is marketed by Amylin Pharmaceuticals, Inc as Symlin.
  • Rifamixin for the Prevention of Traveler’s Diarrhea?

    Rifamixin, a nonabsorbed oral antibiotic, is effective for preventing traveler's diarrhea, according to new research.
  • Vitamin E, Donepezil and MCI

    By Norman R. Relkin, MD, PhD Associate Professor of Clinical Neurology and Neuroscience at New York Presbyterian Hospital-Cornell Campus. Dr. Relkin is on the speaker's bureau of Pfizer, Eisai, and Athena Diagnostics and does research for Pfizer and Merck.
  • Clinical Briefs By Louis Kuritzky, MD

    White-Coat HTN Make Diabetics Walk Treatment of Complicated Grief
  • Does Stress Management Improve Markers of Cardiovascular Disease?

    By Ralph R. Hall, MD, FACP Emeritus Professor of Medicine, University of Missouri, Kansas City School of Medicine Disclosure; Dr. Hall is a consultant for Sanofi-Aventis. Synopsis: Exercise and stress management improved markers of cardiovascular disease more than usual care alone.
  • Fluid Balance in Runners: Getting it Right

    By Joseph E. Scherger, MD, MPH Clinical Professor, University of California, San Diego Disclosure; Dr. Scherger reports no financial conflicts to this field of study.
  • Cardiac Resynchronization Therapy in CHF Who and When

    By Harold L. Karpman, MD Clinical Professor of Medicine, UCLA School of Medicine Disclosure; Dr. Karpman reports no financial conflicts of interest in this field of study. Despite the recent explosion of pharmacologic agents available for the treatment of congestive heart failure (CHF), many patients continue to be severely symptomatic and their prognosis remains poor.
  • Rifaximin to Control Travelers’ Diarrhea

    By Malcolm Robinson, MD, FACP, FACG Emeritus Clinical Professor of Medicine, University of Oklahoma College of Medicine, Oklahoma City, OK Disclosure; Dr. Robinson serves as a consultant for TAP, Pfizer, Janssen, Eisai, J&J-Merck, and Procter & Gamble, is on the speakers bureau of Janssen, Eli Lilly, Solvay, TAP, and Aventis, and does research for Forest Labs, Wyeth-Ayerst, AstraZeneca,and Centocor. Synopsis: Rifaximin, a newly released nonabsorbed antibiotic, appears to safely and effectively prevent the onset and substantial morbidity of travelers diarrhea.
  • Pharmacology Update Ibandronate Sodium Tablets (BonivaTM)

    By William T. Elliott, MD, FACP, and James Chan, PharmD, PhD Dr. Elliott is Chair, Formulary Committee, Northern California Kaiser Permanente; Asst. Clinical Professor of Medicine, University of California, San Francisco; Dr. Chan is Pharmacy Quality and Outcomes Manager, Kaiser Permanente, Oakland, CA Drs. Chan and Elliott report no financial relationships to this field of study.
  • Clinical Briefs By Louis Kuritzky, MD

    Staphylococcal Toxins in Patients with Psoriasis, Atopic Dermatitis, Erythroderma, and in Healthy Control Subjects; Insulin Resistance and Risk of Congestive Heart Failure; Ciprofloxacin Interacts with Thyroid Replacement Therapy